UrologyNews.net

Urology Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Medical Meeting

Immunotherapy has shown promising results in first and second line treatment of metastatic bladder cancer in two phase II trials presented at the ESMO ( European Society for Medical Oncology ) Congres ...


Body mass index ( BMI ) has been associated with worse outcomes in several solid malignancies. A study has evaluated the association between BMI and oncological outcomes in patients treated with radic ...


Preclinical urothelial carcinoma models suggest activity of Dasatinib ( Sprycel ), an oral Src-family kinase ( SFK ) inhibitor. Researchers have determined the feasibility and biologic activity of n ...


Researchers have evaluated the association of ABO blood type with clinicopathologic outcomes and mortality among patients with urothelial carcinoma of the bladder treated with radical cystectomy. 2 ...


Late recurrence of renal cell carcinoma is not a rare event. A retrospective study has investigated the clinicopathological features and the outcome of patients treated with Sorafenib ( Nexavar ), Sun ...


Researchers aimed to identify clinical predictors of long-term response to Abiraterone [ Zytiga ] ( defined as more than 12 months drug exposure ) in a retrospective cohort of metastatic castration-re ...


Pancreatic metastases from renal cell carcinoma are uncommon and their prognostic significance is not well defined. Br> An analysis has evaluated the outcome of patients with pancreatic metastas ...


Studies investigating the association of food and nutrient consumption with the risk of urothelial cell carcinoma ( UCC ) have produced mixed results. Researchers used three common dietary scores, t ...


Little is known about the outcomes and prognostic factors of adjuvant chemotherapy for locally advanced penile squamous cell carcinoma after regional lymphadenectomy ( LAD ). Researchers have retro ...


The efficacy and safety of a combination of chemotherapeutic agent compared with single-agent chemotherapy in the second-line setting of advanced urothelial carcinoma ( UC ) are unclear. Researchers ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Tecentriq ( Atezolizumab ) for the treatment of people with locally advanced or metastatic urothelial carcinoma ( mUC ...


Ureteral stent-related pain is a well-known side effect of stent placement. To date, there is a paucity of resources that address this topic. Stent pain pathophysiology is multifactorial and likely ...


The results from the STRIVE trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in men with castration-resistant prostate cancer ( CRPC ) are published in the Journal of Clinical Onc ...


The results from the phase 2 TERRAIN trial of Enzalutamide ( Xtandi ) compared to Bicalutamide ( Casodex ) in metastatic castration-resistant prostate cancer ( CRPC ) are published in the Lancet Oncol ...


Recent guidelines recommend against routine screening for prostate cancer, partly because of the risks associated with overtreatment of clinically indolent tumours. A study aimed to determine the ...